Based on the discoveries of AURKA–AKT signaling pathway, HUH7-TRCs and PLC/PRF/5-TRCs were treated with alisertib, which was found to be the most HCC-TRCs–targeted drug (Fig. 2D). The gene discussed is MIR7-3HG; the disease is hepatocellular carcinoma.